This bill provides continuing appropriations for federal government operations through October 31, 2025, ensuring that agencies can maintain essential services without interruption. It authorizes funding for departments including Defense, Health and Human Services, Veterans Affairs, and Transportation, while extending specific programs like community health centers, Medicare services, and veterans' benefits. Key provisions include maintaining funding levels for existing programs, extending deadlines for various health and human services initiatives through October 2025, and providing specific amounts for programs like the WIC food assistance program. The bill also includes numerous extensions for programs that would otherwise expire, such as the National Health Service Corps and certain Medicare payment adjustments. This continuing resolution prevents government shutdowns by providing temporary funding until a full fiscal year 2026 appropriations bill can be enacted.
Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl Act This act permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Under the act, offenses involving fentanyl-related substances are triggered by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving 100 grams or more trigger a 10-year mandatory minimum prison term). Additionally, the act establishes a new, alternative registration process for certain schedule I research. The act also makes several other changes to registration requirements for conducting research with controlled substances, including permitting a single registration for related research sites in certain circumstances, waiving the requirement for a new inspection in certain situations, and allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration. Finally, the act expresses the sense that Congress agrees with the interpretation of the Controlled Substances Act in United States v. McCray , a 2018 case decided by the U.S. District Court for the Western District of New York. In that case, the court held that butyryl fentanyl, a controlled substance, can be considered an analogue of fentanyl even though, under the Controlled Substances Act, the term controlled substance analogue specifically excludes a controlled substance.
